TMBCZG

Developed for: vascular dementia
Investigated by: Beijing Compete Medical Technology Development Co. Ltd. · Beijing Union pharmaceutical factory II · Dongzhimen Hospital, Beijing

today NCT03230071 · Ph 2

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT03230071	Jul 2017 → Aug 2019	vascular dementia	Dongzhimen Hospital, Beijing	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	TMBCZG	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03230071 ↗